Friday, October 09, 2015 9:02:57 AM
Self imposed timelines are irrelevant as they never come close to meeting them or are held accountable.
They announce they are going to revert to traditional clinical reporting standards and a few weeks later do exactly the opposite and report on the dosing of a single patient.
The IPO was a complete and utter disaster, with the net proceeds of $12M a pittance. The IPO should have been cancelled.
The company cannot sell itself to anyone, retail investors, big pharma or institutions.
A change of leadership is long overdue and the time for shareholders to stop looking at every move they make in the most optimistic fashion has long passed. No other company I have ever followed has been given as many free passes while proving incompetent to the degree that this company has.
As it stands the destruction of shareholder value is borderline fiduciary fraud. The price of a share now is near the pre consolidation level for the ASX listing of BLT. Less than two cents a share.
Currently Peter French is on Australian TV talking about efficacy results in 18 months. It is a broken record. Again, borderline fraud as the company's website lists Q4 2015 as the beginning of efficacy data.
While I realize this is a harsh analysis of the actions of Mgmt. and the BOD, the time has come to hold them responsible and change is desperately needed in both the marketing/business development team as well as the CEO. Dr. French has proven incompetent as a CEO. He is on record as describing himself as the "reluctant CEO". He has proven it. What is truly amazing is that the BOD and shareholders have allowed his non performance to be handsomely rewarded. Greg West and Carl Stubbings need to be out of jobs for the handling of the IPO and all of the excuses that have been trotted out as to why it was so dismal hold no water as many have pointed out on other forums.
A perfect example of paying for something and getting nothing in return is Tribetarna.
Unfortunately, Benitec paid between $2.7 - $3 Million dollars to a CRO in Eastern Europe: http://www.benitec.com/documents/1309_Van_Leeuwehoek_Research_Update.pdf
P. 14 of above document:
Benitec appointed Europe based Clinical Trials Group CTGCRO to manage the initial
clinical development of Tribetarna and a proposed P
hase I/IIa clinical trial with the
company aims to start in 2014Q4.
One quarter of the monies raised from the IPO was spent on salaries for 2015, one quarter of the IPO was wasted on a CRO payment that I highly doubt is refundable (when the long awaited annual report is out perhaps we will find some clues as to whether we will ever see the money again). Incompetence has reigned for far too long, I for one am done with allowing it to go on without a vocal opposition. I will vote down the remuneration package at the AGM and I will continue to voice my disgust directly to the company via their investors page as is the right of every shareholder.
TT-034, it has long been argued by Mark Kay and others may have a very fatal flaw. The vector.
So unfortunately, this company in fact has proven that they do "enter into agreements for something that is not working".
Recent BNTC News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:17:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:13:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:12:19 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/06/2024 05:15:18 AM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 02/26/2024 02:06:56 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/23/2024 09:09:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 01:15:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 01:01:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:15:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/30/2023 12:31:00 PM
- Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference • GlobeNewswire Inc. • 11/17/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:03:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:00:49 PM
- Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/20/2023 08:31:26 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/20/2023 10:04:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:29:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/28/2023 09:19:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/21/2023 12:05:29 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/21/2023 12:00:53 PM
- Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 09/21/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 09:26:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 09:13:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 08:01:00 PM
- Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering • GlobeNewswire Inc. • 08/11/2023 05:00:12 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM